UZ Leuven — Sponsor Intelligence | 72 EU Trials

Filter these 72 trials by condition, phase, country and more.

Open in Search →

72 Registered trials

41 Recruiting

22 Completed trials

6 Countries active

111 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 11 Phase II/III: 4 Phase II: 13 Phase I/II: 2 Phase III/IV: 6 Phase IV: 31 Phase I: 1 Phase I (Other): 4

Oversight events:

2 temporary halts 1 corrective measure across 2 trials

View oversight register →

100%

22 of 22 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rheumatoid arthritis 2 Coronary artery disease 1 Acute myocardial infarction 1 Cardiac rehabilitation therapy 1 Colon cancer 1 Obesity 1 Breast cancer female 1 Malignant melanoma 1 Stress 1 Atrial fibrillation 1 Chronic rhinosinusitis with nasal polyps 1 Crohn's disease 1

Top IMPs

OXYTOCIN 6 [AL[18F]F]FAPI-74 3 SODIUM CHLORIDE 3 DEXAMETHASONE PHOSPHATE 2 DICLOFENAC SODIUM 2 ENZALUTAMIDE 2 GUSELKUMAB 2 SEMAGLUTIDE 2 [18F]ALF-NOTA-OCTREOTIDE 1 ABEMACICLIB 1 ABIRATERONE ACETATE 1 ALUMINIUM OXIDE, HYDRATED, ALUMINIUM OXIDE, MAGNESIUM HYDROXIDE 1

All trials — page 2

72 total

An exploratory study of [18F]AlF-NOTA-octreotide high resolution NeuroEXPLORER PET and MRI in carotid artery disease Recruiting

2024-515636-77-00 Phase II 1 country [18F]ALF-NOTA-OCTREOTIDE
INtra-tumor miCro dosIng in PatIents with advanced malignant mElanoma receiving aNti-PD1 Therapy. A pilot study. Recruiting

2023-510544-21-00 Phase I (Other) 1 country
FAPIDO Recruiting

2024-512059-19-00 Phase II/III 1 country [AL[18F]F]FAPI-74; IOXITALAMATE MEGLUMINE
PRESENT: Primary care dySpEpsia rikkuNshiTo Recruiting

2024-515756-20-00 Phase III 1 country RIKKUNSHITO
In vivo quantification of Hsp90 in the human brain in healthy aging and neurodegeneration using the novel PET radioligand [11C]HSP990 Recruiting

2023-510532-36-00 Phase I 1 country
Add-on Clioquinol in drug-resistant epilepsy: an exploratory study Recruiting

2024-511388-27-04 Phase II 1 country CLIOQUINOL
Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin a… Recruiting

2023-505253-41-01 Phase III 1 country OXYTOCIN
Budesonide as a treatment for inflammation in stomach complaints. Recruiting

2024-517035-43-00 Phase IV 1 country BUDESONIDE
A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina… Recruiting

2022-502272-23-00 Phase II 1 country ABEMACICLIB; BICALUTAMIDE
STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: the STRADA-CEF tr… Recruiting

2022-502013-28-00 Phase IV 1 country
Prospective head-to-head comparison of cardiac [18F]-MFBG PET versus [123I]-MIBG SPECT in the differentiation between Parkinson’s disease an… Recruiting

2023-506508-18-00 Phase II/III 1 country
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthriti… Recruiting

2023-506638-59-01 Phase IV 1 country RITUXIMAB
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting

2022-502254-13-00 Phase III 1 country ABIRATERONE ACETATE; APALUTAMIDE; CABAZITAXEL; DAROLUTAMIDE; DOCETAXEL; ENZALUTA…
ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting

2023-503533-21-00 Phase II 3 countries
Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting

2022-502082-22-00 Phase III/IV 1 country SEMAGLUTIDE
Evaluation of oxytocin treatment in children with autism and intellectual disability’, Multiple-dose Oxytocine - ASD and Intellectual Disabi… Recruiting

2024-513436-14-00 Phase III/IV 1 country OXYTOCIN
Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome Recruiting

2022-501780-41-00 Phase III 1 country EBASTINE; MEBEVERINE HYDROCHLORIDE
Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting

2022-500311-39-00 Phase IV 2 countries GUSELKUMAB; MIRIKIZUMAB
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting

2022-502373-42-00 Phase III 1 country DEGARELIX; ENZALUTAMIDE; GOSERELIN ACETATE; LEUPRORELIN ACETATE; RELUGOLIX; TRIP…
Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long-term parenteral nutrition. Recruiting

2024-512061-14-00 Phase IV 1 country
Brain Injury and Ketamine: a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy inte… Recruiting

2023-505319-19-00 Phase III/IV 1 country KETAMINE
The effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers. Recruiting

2024-518641-21-00 Phase IV 1 country LIRAGLUTIDE
Clebopride for the treatment of Rumination Recruiting

2024-516573-71-00 Phase IV 1 country CLEBOPRIDE HYDROGEN MALEATE
Cognitive brain circuits and the spread of tau in vivo in humans Recruiting

2024-511613-38-01 Phase III/IV 1 country FLORQUINITAU (18F)

Showing 25–48 of 72 trials

← All sponsors A–Z